PROPOSED RULE MAKING



CR-102 (December 2017) (Implements RCW 34.05.320)

Do NOT use for expedited rule making

CODE REVISER USE ONLY

OFFICE OF THE CODE REVISER STATE OF WASHINGTON FILED

DATE: December 03, 2020

TIME: 4:17 PM

WSR 21-01-021

Agency: Health Care Authority																
⊠ Original Notice																
□ Supplemental Notice to WSR																
□ Continuance of WSR □ Preproposal Statement of Inquiry was filed as WSR 19-14-098; or □ Expedited Rule MakingProposed notice was filed as WSR; or																
								□ Proposal is exempt under RCW 34.05.310(4) or 34.05.330(1); or								
								□ Proposal is exempt under RCW								
Title of rule and other identifying information: (describe subject) WAC 182-530-7900 Drugs purchased under the Public Health Service (PHS) Act.																
Hearing location(s):																
Date:	Time:	Location: (be specific)	Comment:													
January 26, 2021	10:00 AM	In response to the coronavirus disease 2019 (COVID-19) public health emergency, the agency will not provide a physical location for this hearing. This promotes social distancing and the safety of the citizens of Washington State. A virtual public hearing, without a physical meeting space, will be held instead.	The attend the virtual public hearing, you must register at the following link: https://attendee.gotowebinar.com/register/5895859935 949871883. Webinar ID: 563-710-843 After registering, you will receive a confirmation email containing the information about joining the webinar.													
Date of intended adoption: Not sooner than January 27, 2021 (Note: This is NOT the effective date)																
Submit written comments to: Name: HCA Rules Coordinator Address: PO Box 42716, Olympia WA 98504-2716 Email: arc@hca.wa.gov Fax: (360) 586-9727 Other: By (date) January 26, 2021																
Assistance for persons with disabilities:																
Contact Amber Loughe Phone: (360) 725-1349 Fax: (360) 586-9727 TTY: Telecommunicat Email: amber.loughee Other: By (date) January 8, 2	eed 9 ion Relay Se d@hca.wa.g	ervices (TRS): 711														

The agency previously filed this proposal under WSR 20-02-073, and held a public hearing on February 4, 2020. Stakeholder comments and then the subsequent public health emergency further delayed this rulemaking. In accordance with RCW 34.05.335(3), the agency is refiling this proposal without change and will hold a second public hearing. Comments and testimony that were previously submitted on this proposal under WSR 20-02-073 will be included in the agency's Concise Explanatory Statement (CES).							
The agency is revising this section to clarify that as part of participation in the 340B program, providers must agree, via an annual attestation form, that all claims for Washington Apple Health clients in both fee-for-service and managed care are subject to their respective 340B rules. The agency is amending subsection (4) to include under the Medicaid fee-for-service program.							
Reasons support	ting proposal: See Purpose						
Statutory authority for adoption: RCW 41.05.021, 41.05.160							
Statute being imp	plemented: RCW 41.05.021	, 41.05.160					
Is rule necessary	because of a:						
Federal Lav			□ Yes ⊠ No				
Federal Co	□ Yes ⊠ No						
State Court If yes, CITATION:			☐ Yes ☒ No				
matters: N/A							
Name of propone	ent: (person or organization)	Health Care Authority	□ Private□ Public⊠ Governmental				
Name of agency	personnel responsible for:						
	Name	Office Location	Phone				
Drafting:	Valerie Freudenstein	PO Box 42716, Olympia WA 98504-2716	360-725-1344				
Implementation:	Natalia Oxford Wilson	PO Box 45510, Olympia, WA 98504-5510	360-725-1861				
Enforcement:	Natalia Oxford Wilson	PO Box 45510, Olympia, WA 98504-5510	360-725-1861				
Is a school districtly lf yes, insert states	-	required under RCW 28A.305.135?	□ Yes ⊠ No				
The public may Name: Address Phone: Fax: TTY: Email: Other:		district fiscal impact statement by contacting:					

Purpose of the proposal and its anticipated effects, including any changes in existing rules:

ls a c	ost-be	nefit analysis required under RCW 34.05.	328?	
	Yes:	A preliminary cost-benefit analysis may be	obtained by	contacting:
	Na	ime:		
	Ad	dress:		
		one:		
	Fa			
	TT			
		nail:		
		her:		
		Please explain: RCW 34.05.328 does not a rative Rules Review Committee or applied versions.		th Care Authority rules unless requested by the Joint
Regu	latory	Fairness Act Cost Considerations for a S	mall Busine	ess Economic Impact Statement:
		posal, or portions of the proposal, may be e 5 RCW). Please check the box for any appli		requirements of the Regulatory Fairness Act (see otion(s):
				CW 19.85.061 because this rule making is being
				ations. Please cite the specific federal statute or
_		is rule is being adopted to conform or compl	y with, and c	lescribe the consequences to the state if the rule is not
adopt		description:		
		•	mpt because	e the agency has completed the pilot rule process
		CW 34.05.313 before filing the notice of this	•	• • • • • • • • • • • • • • • • • • • •
		_		ne provisions of RCW 15.65.570(2) because it was
		a referendum.	•	` ` ` ,
□ Tr	nis rule	proposal, or portions of the proposal, is exe	mpt under R	CW 19.85.025(3). Check all that apply:
		RCW 34.05.310 (4)(b)		RCW 34.05.310 (4)(e)
		(Internal government operations)		(Dictated by statute)
		RCW 34.05.310 (4)(c)		RCW 34.05.310 (4)(f)
	Ш	(Incorporation by reference)	Ш	(Set or adjust fees)
		• • •		RCW 34.05.310 (4)(g)
		RCW 34.05.310 (4)(d)		() (3)
		(Correct or clarify language)		((i) Relating to agency hearings; or (ii) process
				requirements for applying to an agency for a license or permit)
□ Th	nis rule	proposal, or portions of the proposal, is exe	mpt under R	CW .
		of exemptions, if necessary:	•	
		-		
		COMPLETE THIS SECTION	ON ONLY IF	NO EXEMPTION APPLIES
If the	propos	ed rule is not exempt , does it impose more	-than-minor	costs (as defined by RCW 19.85.020(2)) on businesses?
\boxtimes	No	Briefly summarize the agency's analysis sh	owing how c	osts were calculated. The proposed rule does not
im	pose a	ny costs on businesses.	· ·	·
				e-than-minor cost to businesses, and a small business
ec	onomic	c impact statement is required. Insert statem	ent here:	
	The p	• • • • • • • • • • • • • • • • • • • •	s economic	impact statement or the detailed cost calculations by
		ime:		
		dress:		
		one:		
	Fa			
	TT			
		nail:		
		her:		

Date: December 3, 2020	Signature:	
Name: Wendy Barcus	Wandy Borous	
Title: HCA Rules Coordinator		

- WAC 182-530-7900 Drugs purchased under the Public Health Service (PHS) Act. (1) Providers dispensing or administering 340B drugs to Washington apple health clients are required to submit their valid medicaid provider number(s) or national provider identification (NPI) number to the PHS health resources and services administration, office of pharmacy affairs. See WAC 182-530-7500 for information on the drug rebate program.
- (2) Drugs purchased under section 340B of the Public Health Service (PHS) Act can be billed to Washington apple health only by PHS-qualified entities. The Washington medicaid rebate process excludes 340B claims from invoicing only when the drug is billed by a medicaid provider number or national provider identification (NPI) number listed on the PHS office of pharmacy affairs national medicaid exclusion file. See WAC 182-530-7500 for information on the drug rebate program.
- (3) As part of participation in the 340B program, providers must submit a completed annual attestation form (HCA 13-0047) to the agency acknowledging that all claims for Washington apple health clients in both fee-for-service and managed care are subject to their respective 340B rules. Providers who fail to submit a completed attestation form to the agency may receive a compliance audit and be at risk of duplicate discounts.
- $\underline{(4)}$ With the exception of claim types identified in subsection $((\frac{(4)}{(4)}))$ of this section, all 340B purchased drugs <u>under the medicaid fee-for-service program</u> must be billed to the medicaid agency at the 340B actual acquisition cost (340B AAC).
- ((4))) (5) Exceptions to the 340B AAC billing requirement are only made for:
- (a) Outpatient hospital claims paid under the enhanced ambulatory payment group (EAPG) methodology (see WAC 182-550-7000); and
- (b) Ambulatory surgery claims paid under payment groups methodology.